Show simple item record

dc.contributor.authorPowles, T
dc.contributor.authorLarkin, JMG
dc.contributor.authorPatel, P
dc.contributor.authorPerez-Valderrama, B
dc.contributor.authorRodriguez-Vida, A
dc.contributor.authorGlen, H
dc.contributor.authorThistlethwaite, Fiona C
dc.contributor.authorRalph, Christy
dc.contributor.authorSrinivasan, G
dc.contributor.authorMendez-Vidal, MJ
dc.contributor.authorLiu, WK
dc.contributor.authorPrendergast, A
dc.contributor.authorVosper, L
dc.contributor.authorMousa, K
dc.contributor.authorSuarez, C
dc.date.accessioned2019-11-19T16:01:09Z
dc.date.available2019-11-19T16:01:09Z
dc.date.issued2019en
dc.identifier.citationPowles T, Larkin JMG, Patel P, P�rez-Valderrama B, Rodriguez-Vida A, Glen H, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). J Clin Oncol. 2019;37(7_suppl):545-.en
dc.identifier.doi10.1200/JCO.2019.37.7_suppl.545en
dc.identifier.urihttp://hdl.handle.net/10541/622476
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.7_suppl.545en
dc.titleA phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentBarts Cancer Institute, Royal Free NHS trust, St. Bartholomew�s Hospital, London, United Kingdom; The Royal Marsden Hospital, Londonen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record